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 Combined antibiotic & anti-virulence drugs can clear antibiotic-resistant infections.
 Delay between delivery of drug types can render the treatment successful.
 Fitness cost associated with antibiotic-resistance shapes the optimal treatment.
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a b s t r a c t
Bacterial resistance to antibiotic treatment is a huge concern: introduction of any new antibiotic is
shortly followed by the emergence of resistant bacterial isolates in the clinic. This issue is compounded
by a severe lack of new antibiotics reaching the market. The signiﬁcant rise in clinical resistance to
antibiotics is especially problematic in nosocomial infections, where already vulnerable patients may fail
to respond to treatment, causing even greater health concern. A recent focus has been on the
development of anti-virulence drugs as a second line of defence in the treatment of antibiotic-
resistant infections. This treatment, which weakens bacteria by reducing their virulence rather than
killing them, should allow infections to be cleared through the body's natural defence mechanisms. In
this way there should be little to no selective pressure exerted on the organism and, as such, a
predominantly resistant population should be less likely to emerge. However, before the likelihood of
resistance to these novel drugs emerging can be predicted, we must ﬁrst establish whether such drugs
can actually be effective. Many believe that anti-virulence drugs would not be powerful enough to clear
existing infections, restricting their potential application to prophylaxis. We have developed a
mathematical model that provides a theoretical framework to reveal the circumstances under which
anti-virulence drugs may or may not be successful. We demonstrate that by harnessing and combining
the advantages of antibiotics with those provided by anti-virulence drugs, given infection-speciﬁc
parameters, it is possible to identify treatment strategies that would efﬁciently clear bacterial infections,
while preventing the emergence of antibiotic-resistant subpopulations. Our ﬁndings strongly support
the continuation of research into anti-virulence drugs and demonstrate that their applicability may
reach beyond infection prevention.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Bacterial resistance to antibiotic agents is an increasing problem
in modern society. The introduction of every new class of antibiotic
(from the original β-lactam, penicillin, to the more recent lipopep-
tides such as daptomycin) has been followed by the emergence of
new strains of bacteria resistant to that class, many emerging in the
clinic only a few years after the introduction of the drug (Butler and
Buss, 2006; Clatworthy et al., 2007; Lewis, 2013). Given that the
pace of antibiotic discovery has dramatically slowed down (most
classes of antibiotic were discovered in the 1940s to the 1960s, the
‘Golden Era’ of antibiotics, with the past 40 years giving us only ﬁve
signiﬁcant new classes (Butler and Buss, 2006; Lewis, 2013) and
pharmaceutical companies devoting less research into discovering
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new antibiotics (Projan and Shlaes, 2004; Mellbye and Schuster,
2011), this poses a huge problem. Development of novel treatments
for bacterial infections is of utmost importance.
Traditional antibiotics are classed either as bactericidal or bacter-
iostatic, working to kill bacteria or inhibit bacterial growth respec-
tively (Clatworthy et al., 2007; Mellbye and Schuster, 2011). While
effective in eliminating susceptible bacterial infections, antimicro-
bials impose selective pressure on the bacteria, leading to the rise of
resistant clones within the bacterial population. Resistance can be
acquired either through spontaneous chromosomal mutation and
then selection by antibiotic use, known as vertical evolution, or
through acquiring genetic material from other resistant organisms,
known as horizontal evolution (Tenover, 2006). Horizontal evolution
occurs via mechanisms such as conjugation, transformation and
transduction (Alanis, 2005) and can take place between strains of
the same or different bacterial species. Horizontal evolution can lead
to multidrug resistance and is a major concern in hospitals where
resistant bacteria are able to remain viable despite antibiotic use and
are the cause of many serious nosocomial infections in already
vulnerable patients (Alanis, 2005; Tenover, 2006).
It has been suggested that the focus of new drug development
should be on targeting virulence, the bacteria's ability to cause
disease (Clatworthy et al., 2007), but this approach remains
controversial both in terms of its potential efﬁcacy and its ability
to counter microbial resistance. Anti-virulence drugs would mini-
mise any harm caused by bacteria while they remain in the host
until they can be cleared by natural defences. This can occur either
by being ﬂushed out of the system or by being eradicated by the
host's immune response. This should exert little to no selective
pressure on the bacteria but this has not yet been proved in vivo.
Anti-virulence drugs could target a range of mechanisms, includ-
ing bacterial adhesion to host cells, toxin delivery or virulence
gene regulation, all necessary for successful infection (Clatworthy
et al., 2007; Mellbye and Schuster, 2011) and many of these are
under investigation. In the vast majority of cases these approaches
have proved to attenuate but not clear infection and often only
when used in infection-prevention (as opposed to post-infection
treatment), see for example Hentzer et al. (2003), Rasmussen et al.
(2005), Wright et al. (2005), Jakobsen et al. (2012), Curtis et al.
(2014), Hraiech et al. (2014), Sully et al. (2014) (quorum sensing
and signalling inhibitors), Felise et al. (2008) (secretion inhibitor),
Krachler et al. (2012) (adhesion inhibitor), Liu et al. (2008) (direct
modulator of the bacteria's ability to suppress an immune
response) and Hung et al. (2005) (colonisation inhibitor).
We adopt a modelling approach to investigate the viability of anti-
virulence drugs in silico. Our results suggest that, in combination with
antibiotics and under speciﬁc treatment strategies, anti-virulence
drugs can be effective in clearing bacterial infections where antibiotic
resistance is a concern. Optimal treatment strategies are likely to be
speciﬁc to the patient, infection and bacterial strain and (rather than
attempt to pin-point exact strategies) we use this theoretical frame-
work as a “proof of concept”, exploiting parameter surveys to
investigate a range of scenarios, highlighting the potential and the
need for targeting infections with tailored treatments in the future.
Given that every patient, infection and strain of bacteria are different,
it is impossible to obtain a conclusive set of parameters which will suit
all situations. We therefore exploit parameter surveys to ascertain
under what conditions certain behaviour will occur.
This work lays the foundations for more detailed models incor-
porating mechanisms of speciﬁc types of anti-virulence drugs. This
will facilitate testing of the likelihood that microbial resistance to
these novel drugs could emerge. We address this brieﬂy in Section 4
but leave this largely to further work due to the vast array of targets
and resistance mechanisms that can be associated with anti-virulence
drugs. Unless explicitly stated otherwise therefore, the description
‘resistant’ refers only to antibiotic-resistance in this work.
2. Materials and methods
2.1. Model formulation
There are two main approaches usually takenwhen modelling the
emergence of antibiotic-resistant bacteria: within-host models, or
within-hospital compartmental models. Models of hospital resistance
usually follow a similar form to the classic “Susceptible–Infectious–
Resistant” (SIR) models of epidemiology, looking speciﬁcally at how
nosocomial infections will spread throughout the hospital, for exam-
ple Austin and Anderson (1999), Lipsitch et al. (2000), andWebb et al.
(2005). While such models are useful to develop strategies to prevent
the spread of resistance, our focus is on treatment strategies to
eliminate the emergence of an antibiotic-resistant subpopulation that
has either arisen through random mutation and clonal expansion or
through cross-contamination within a particular infection and under
a speciﬁc treatment regimen. If the resistant bacteria within a single
host can be eliminated then the spread of resistance throughout the
hospital is a less pressing concern.
Existing mathematical models that focus on the within-host
emergence of antibiotic-resistance examine how treatment strate-
gies can both cause and be adapted to prevent the emergence of
antibiotic resistance, for example Lipsitch and Levin (1997) and
D'Agata et al. (2008). Such models often neglect the effect of the host
immune response, assuming it to be negligible or constant under the
effect of the antibiotic. Since the efﬁcacy of anti-virulence drugs will
depend at least in part on the host's innate immunity, we include
cell-mediated innate immune response in the model.
The system consists of ﬁve interacting components: popula-
tions of antibiotic-susceptible bacteria (S), antibiotic-resistant
bacteria (R) and immune cells e.g. phagocytes (P), and concentra-
tions of antibiotic (A) and anti-virulence drug (An). These interact
as demonstrated in Fig. 1 and represent a generalised model of a
local bacterial infection, such as a urinary tract or wound infection.
The growth of bacteria within a host is likely to saturate over time
as a result of space and nutrient limitations. We therefore use a
logistic growth term with baseline growth rate ηi, ði¼ S;RÞ and a
combined carrying capacity K, rather than simple exponential growth,
to represent the bacterial dynamics. We include a removal rate, ψ,
representing the body's endogenous, physical clearance mechanisms
(this can be expected to vary depending upon infection type).
Due to the potential for multidrug resistance (Tenover, 2006), the
primary cause for concern in hospitals is resistance due to horizontal
evolution: acquiring new genetic material from other resistant
organisms. Horizontal evolution involves the transfer of the resistance
gene, normally found in sections of DNA known as transposons, from
one plasmid to another. This takes place via one of three main
mechanisms: conjugation, transformation or transduction (Alanis,
2005; Tenover, 2006). We focus on the most common of the three
transmission mechanisms conjugation (Alanis, 2005), whereby one
bacterium transfers plasmid containing the genes for resistance to an
adjacent bacterium. Research suggests that these plasmid-bearing,
and thus antibiotic-resistant, bacteria are subject to a ﬁtness cost, c,
lowering their growth rate (Levin et al., 1997; Austin and Anderson,
1999; Bergstrom et al., 2000; Lipsitch et al., 2000; Lipsitch, 2001),
hence we choose the growth rate ηR ¼ ð1cÞηS where 0oco1.
Since this plasmid transfer occurs between adjacent bacteria, and we
assume a well mixed population, we represent this interaction
through mass action kinetics with a conjugation rate, λ, proportional
to the levels of both antibiotic-susceptible and -resistant bacteria in
the population (Bergstrom et al., 2000; Webb et al., 2005; Imran and
Smith, 2006; D'Agata et al., 2008). It has also been observed that it is
possible to lose the plasmid carrying the resistance genes (Webb
et al., 2005; Imran and Smith, 2006) and so this too is incorporated
into the model via a constant reversion rate, ρ.
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We assume that bacteria are consumed by phagocytes (immune
cells) at rate γ. We note that the inclusion of a saturating effect on
immune cell action, as seen in Malka et al. (2010), has no signiﬁcant
effect on the results in this study andwe therefore omit it for simplicity.
Rather than assuming a constant phagocyte level, as is often done, we
incorporate a more realistic representation of cell-based, innate
immune response into the model. Using a logistic style term, phago-
cytes are recruited to the site of infection at a rate proportional to the
amount of bacteria present subject to an infection-site-speciﬁc, pha-
gocytic carrying capacity, Pmax (Smith et al., 2011). Phagocytes are lost
through pathogen-induced apoptosis (at rate δ) and natural clearance
(at rate δP) (Zysk et al., 2001).
Antibiotic is either administered in one dose or assumed to be
present at constant level (e.g. intravenous delivery) and rapidly
absorbed to the site of infection (Austin and Anderson, 1999).
Elimination of the antibiotic from the system, due to both degrada-
tion of the drug and clearance due to natural ﬂow through the body,
is assumed to be independent of the bacterial population and
follows ﬁrst order kinetics (Austin and Anderson, 1999; Imran and
Smith, 2006). The effect of the antibiotic on each bacteria type is
modelled using a saturating response, EimaxA=ðAi50þAÞ, subject to a
maximum killing rate Eimax and the antibiotic concentration required
for half maximum effect, A50i , for i¼ S;R (Lipsitch and Levin, 1997;
Austin and Anderson, 1999; Nikolaou and Tam, 2006; Imran and
Smith, 2007). Note that resistant bacteria are in reality often only
partially resistant, thus in general we assume ERmaxa0 but
ERmaxoESmax (Lipsitch and Levin, 1997).
We assume that the anti-virulence drug increases the effec-
tiveness of the host's immune response by weakening the bacter-
ia's ability to counteract the host's immune mechanisms. The vast
majority of bacterial virulence mechanisms interfere with the host
immune response so this approach allows us to capture the action
of a generic anti-virulence drug without needing to model speciﬁc
mechanisms. Some anti-virulence compounds may directly inhibit
the action of bacteria on immune cells (Liu et al., 2008, for
example) while others have been shown to promote host clear-
ance of the bacteria indirectly (e.g. quorum sensing inhibitors in
Hentzer et al. (2003), Rasmussen et al. (2005), Jakobsen et al.
(2012), Sully et al. (2014), or a secretion inhibitor in Felise et al.
(2008)). Interference with adhesion mechanisms will also promote
a host response since secretion systems responsible for production
of virulence factors require host binding to function effectively
(e.g. see Krachler et al., 2012). In order to model this generic anti-
virulence drug mathematically we represent its effect as a satur-
ating response, or Hill equation (Csajka and Verotta, 2006;
Goutelle et al., 2008), with γmax representing the maximum
increased effect of the immune response and γ50, the anti-
virulence drug concentration for half maximum effect. We assume
that the anti-virulence drug has the same effect on both the
antibiotic-resistant and susceptible bacteria.
Combining the above, we obtain the following model of
bacterial population dynamics during antibiotic treatment:
dA
dt
¼ αA; ð1Þ
dAn
dt
¼ κAn; ð2Þ
dP
dt
¼ β SþRð Þ 1 P
Pmax
 
δðSþRÞPδPP; ð3Þ
dS
dt
¼
ηSS 1
SþR
K
 
μSðAÞS γþζ An
  
PS
λSRþρRψS; if SZ1;
ψS; otherwise;
8>><
>>:
ð4Þ
dR
dt
¼
ð1cÞηSR 1
SþR
K
 
μRðAÞR γþζ An
  
PR
þλSRρRψR; if RZ1;
ψR; otherwise;
8>><
>>:
ð5Þ
where the conditions on S;Ro1 are included to ensure bacterial
growth cannot resume in this regime. Here μiðAÞ ¼ EimaxA=ðAi50þAÞ
is the effect of the antibiotic on susceptible and resistant bacteria,
respectively, for i¼ S;R, and ζ An ¼ γmaxAn=ðγ50þAnÞ is the effect
of the anti-virulence drug. Default parameter values and deﬁni-
tions are as given in Table 1, but a range of parameter values are
explored throughout. Unless otherwise speciﬁed, we use the initial
conditions:
Að0Þ ¼ 4 μg=ml; Anð0Þ ¼ 4 μg=ml; Pð0Þ ¼ 0 cells;
Sð0Þ ¼ 6000 cells; Rð0Þ ¼ 20 cells; ð6Þ
representing clinically realistic dosages (for instance 4 μg=ml is a MIC
value for meropenem in Pseudomonas aeruginosa infections, see Liu
et al., 2002) and the antibiotic-resistant subpopulation being in the
minority and introduced via cross-contamination. We note that the
initial conditions for numbers of bacteria are in line with the two
studies from which we have principally sourced our parameter values
– see Table 1, Handel et al. (2009) and Smith et al. (2011). Given that
we are intending to provide a framework for future development of
infection-speciﬁc treatment strategies and not proposing exact strate-
gies here, these initial conditions are sufﬁcient for our purposes.
The equations are solved numerically in Matlab using the solver
ode15s for time-dependent solutions and multi-parameter steady-
state analyses. The software XPPAUT is employed for single para-
meter steady-state surveys (where the S;Ro1 conditions in (4) and
(5) are removed for continuity). We consider three scenarios in our
numerical solutions: an infection is treated by antibiotics alone, by
Fig. 1. Schematic representation of the main interactions involved in an infection
treated by antibiotics and anti-virulence drugs with S (antibiotic-susceptible
bacteria), R (antibiotic-resistant bacteria), P (immune cells, e.g. phagocytes), A
(antibiotic concentration) and An (anti-virulence drug concentration). Both the
phagocytes and antibiotic inhibit bacterial growth, with the antibiotic having a
greater effect on the susceptible bacteria than the resistant ones, assuming only
partial resistance. The anti-virulence drug increases the effectiveness of the
immune response in order to eliminate the bacteria more naturally, working on
both susceptible and resistant bacteria in the same way.
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an anti-virulence drug alone or by both drugs in combination. In
each case we wish to see how effective the treatment strategies are
in lowering bacterial load but crucially also in tackling the emer-
gence of antibiotic-resistant bacteria during the infection.
3. Results
3.1. Antibiotic treatment (Að0Þ ¼ 4 μg=ml, Anð0Þ ¼ 0 μg=ml)
We consider a scenario where the bacterial population at the site of
infection is composed predominantly of an antibiotic-susceptible
subpopulation and a minor, resistant subpopulation which has arisen
through cross-contamination of the site with a resistant population
introduced from an environmental source (as is often the case during
hospital-outbreaks) (Das et al., 2002; Fanci et al., 2009).
Firstly we establish that our parameter set represents an
infection where an initially small subpopulation of antibiotic-
resistant bacteria emerges to become dominant when the infec-
tion is treated with antibiotics. In Fig. 2a (no treatment) suscep-
tible bacteria remain dominant with the ﬁtness costs associated
with resistance meaning the antibiotic-resistant bacteria die out.
One dose of antibiotic is introduced at time 0 in Fig. 2b, quickly
killing the susceptible bacteria and providing an environment in
which the resistant bacteria can ﬂourish. Our parameter set
therefore reﬂects a clinically relevant scenario.
Antibiotics can either be administered in doses (α40) or
continuously (α¼ 0). Our model predicts that under antibiotic
dosing all susceptible bacteria may be eradicated from the infec-
tion, however, as the antibiotic degrades out of the system the
population of resistant bacteria increases exponentially (Fig. 2b
and c). Upon a new dose of antibiotics being administered, the
level of resistant bacteria drops slightly (due to the allowance of
only partial resistance), subsequently quickly rising when the
antibiotic degrades out of the system. Next, we consider constant
antibiotic administration (e.g. via intravenous therapy, Fig. 2d).
Susceptible bacteria are eliminated and the resistant bacteria
reach a lower (but still high) steady state than in the absence of
any drug. Thus the model reﬂects the type of infection in which we
are most interested: one which cannot be cleared by either the
immune system or antibiotics and in which antibiotic-resistance is
a primary concern. For the remainder of this study we consider
only constant antibiotic concentration for mathematical simplicity.
3.2. Antibiotic treatment: parameter analysis
Evidently, the amount of antibiotic administered will have a large
effect on the ﬁnal relative population levels of antibiotic-susceptible
and -resistant bacteria (Fig. 3a). Though some resistant bacteria
persist regardless of the dosage, as a result of the default parameter
set representing only partial resistance, the bacterial load can be
lowered by increasing the quantity of antibiotic administered
(though Að0Þ extends beyond a clinically realistic range in Fig. 3a).
Partial resistance is governed by the two parameters ERmax and
AR50 (the antibiotic's maximum killing rate for resistant bacteria
and the antibiotic concentration for half the maximum effect on
resistant bacteria, respectively). The limits ERmax-0 or A
R
50-1
yield complete resistance, and in Fig. 3b we see what happens
when these parameters are varied in combination. The sensitivity
of the bacteria to a speciﬁc antibiotic determines the bacterial load
that persists in an infection treated by antibiotics: reducing the
resistance level lowers this number.
Though the results so far are in no way surprising, they illustrate
the power of adopting a modelling approach to predict the outcome
of a particular infection: if the infecting strain can be isolated and
the relevant parameters can be determined, it is possible to predict
the number of bacteria remaining at an infection site and therefore
identify an optimal treatment strategy.
We recall that a ﬁtness cost can be incurred as a consequence of
the bacteria bearing the plasmid that confers antibiotic resistance.
It has been shown that, depending on the plasmid in question, the
ﬁtness cost incurred can vary from 0.09 to 0.25 (Subbiah et al.,
2011) as a proportion of the non-plasmid-bearing growth rate, and
that over time this cost can reduce, sometimes eventually dis-
appearing altogether (Dionisio et al., 2005). Thus, it is important to
look at the effect of varying the cost of resistance on the whole
Table 1
Parameter notation with descriptions, estimated values and units. Immune-related parameter values are taken from Smith et al. (2011) and bacteria- and antibiotic-
associated values from Handel et al. (2009). Where no source is given estimates have been made from what we believe to be realistic parameter ranges, in keeping with the
other parameters. In particular β is chosen so that the immune system alone cannot clear the infection, the anti-virulence drug is assumed to have equivalent efﬁciency to the
antibiotic, and λ and ρ are chosen so that an antibiotic-resistant strain can emerge to become dominant during infection under antibiotic selection. While we do not claim
that these parameters represent one particular infection-type, they should fall within a realistic range, enabling us to investigate a spread of scenarios through variations to
these values in the parameter surveys provided throughout the study.
Parameter Description Units Estimated value Source
α Elimination rate of antibiotic under distinct doses days1 3.6 Handel et al. (2009)
Elimination rate of antibiotic under intravenous therapy days1 0 –
κ Elimination rate of anti-virulence drug days1 3.6 –
Elimination rate of anti-virulence drug under intravenous therapy days1 0 –
β Recruitment rate of phagocytes days1 3 –
c Fitness cost of resistance dimensionless 0.1 –
δP Clearance rate of phagocytes days1 1.512 Smith et al. (2011)
δ Bacterial induced death of phagocytes cells1 days1 6 106 Smith et al. (2011)
AS50 Antibiotic concentration for half maximum effect on susceptible bacteria μg/ml 0.25 Handel et al. (2009)
AR50 Antibiotic concentration for half maximum effect on resistant bacteria μg/ml 5 Handel et al. (2009)
ESmax Maximum killing rate of susceptible bacteria days
1 36 Handel et al. (2009)
ERmax Maximum killing rate of resistant bacteria days
1 26.4 Handel et al. (2009)
γ50 Anti-virulence drug concentration for half maximum effect μg/ml 5 –
γmax Maximum increased effectiveness of immune response cells
1 days1 0.035 –
K Carrying capacity of bacteria cells 109 Handel et al. (2009)
ηS Growth rate of susceptible bacteria days
1 24 Handel et al. (2009)
Pmax Maximum number of phagocytes cells 1:8 105 Smith et al. (2011)
γ Bacterial clearance by phagocytes cells1 days1 2:4 104 Smith et al. (2011)
λ Conjugation rate constant days1 105 –
ρ Reversion rate constant days1 106 –
ψ Removal rate days1 0.7 –
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infection (Fig. 4a). We observe that, as expected, a decrease in
ﬁtness cost increases the levels of resistant bacteria, and thus the
level of immune cells (that are recruited in response to the
presence of bacteria), at the infection site. As c-0, the plasmid
is no longer exerting any signiﬁcant metabolic cost on the bacteria
and thus they are in a stronger position when faced with antibiotic
pressure. Similarly, as c increases, we see the bacteria unable to
compete against this antibiotic pressure and once c40:48 (for our
default parameter set), the beneﬁt of resistance no longer out-
weighs the costs incurred and the antibiotic-resistant subpopula-
tion dies out in the long term.
We also ﬁnd that variations to ρ, the rate at which a plasmid-
bearing bacteria loses its plasmid and reverts to being antibiotic-
susceptible (Webb et al., 2005; Imran and Smith, 2006) can cause
signiﬁcant changes in the dynamics of the system (Fig. 4b). There
exists a range of ρ where populations of both antibiotic-resistant
and -susceptible bacteria are maintained in the population at
steady state despite the presence of antibiotic: though the anti-
biotic kills the susceptible bacteria the resistant bacteria rejuve-
nate the susceptible population via plasmid loss. However, a
sufﬁciently fast rate of plasmid loss results in both populations
dying out: the resistant population all revert back to plasmid free
susceptible bacteria leaving no plasmid-bearing bacteria to reju-
venate the population once the antibiotic has taken effect. In
reality we expect this reversion rate to be very low so the situation
whereby only resistant bacteria remain in the population is most
likely (Sorensen et al., 2005).
3.3. Anti-virulence drugs (Að0Þ ¼ 0 μg=ml, Anð0Þ ¼ 4 μg=ml)
We consider how effective anti-virulence drugs alone can be in
treating a bacterial infection without antibiotics. Under our default
parameter set (Fig. 5) the anti-virulence drug eliminates the
antibiotic-resistant bacteria (this subpopulation is weaker due to the
ﬁtness cost imposed on them via the presence of the plasmid).
However, as opposed to an infection treated only by antibiotics where
antibiotic-resistant bacteria persisted, the anti-virulence drug fails
to eliminate all the antibiotic-susceptible bacteria. Encouragingly
though, the total number of bacteria remaining in the system is
much lower than the number remaining after antibiotic treatment.
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Fig. 2. Numerical solutions to (1)–(5) with (a) no treatment (Að0Þ ¼ Anð0Þ ¼ 0), (b) one dose of antibiotic (Að0Þ ¼ 4;Anð0Þ ¼ 0), (c) repeated dosing of antibiotic (A is reset to
4þAðτendÞ at the start of each interval ½τ τendÞ for τ¼ 0:5p, p¼ 1;2;3;…;9, τend ¼ τþ0:5 and Anð0Þ ¼ 0) and (d) constant antibiotic level (Að0Þ ¼ 4;Anð0Þ ¼ 0; α¼ 0). Our
parameter choice reﬂects the situation where the immune system cannot clear the infection and a dominant population of antibiotic-resistant bacteria emerge if treated
with antibiotics. Note that here and in subsequent ﬁgures, we have adjusted the minimum value on the y-axes to enable visualisation of any variables tending to zero.
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Despite the anti-virulence drug making the bacteria more vulner-
able to the immune system there is still a limit to how effective the
immune response can be and hence why some bacteria remain at the
infection site. In modelling recruitment of the immune cells to the
infection site, we imposed a recruitment rate, β, proportional to the
number of bacteria present at the infection site, and a carrying
capacity, Pmax. As such, the presence of immune cells is dependent
on the presence of bacteria. As the drug starts to take effect the
bacterial population diminishes, shortly followed by a decline in
phagocyte population. Since this treatment is based on enabling the
immune system to clear the infection, as the immune cell level
decreases so does the efﬁcacy of the drug; hence we see a possible
reason for the persisting population of susceptible bacteria.
Thus although anti-virulence drugs are capable of dealing with
the presence of antibiotic-resistant bacteria if they grow more
slowly than antibiotic-susceptible bacteria, it may not be an
effective treatment for the infection as a whole. In the following
parameter analysis we consider whether anti-virulence drugs
would ever be capable of clearing an infection or whether they
might be more suitable for infection prevention.
3.4. Anti-virulence drugs: parameter analysis
A crucial aspect of an anti-virulence drug is its dependence on the
immune system to be successful, and as such it may not be able to
fully clear an infection under our default parameter set (Fig. 5). Both
the natural removal rate, ψ, and the baseline immune response, γ, are
not only very difﬁcult to estimate, they are also patient- and site-
speciﬁc. Along with inherent individual differences in patients, we
also see variation within a single host depending on their current
health. Since the main cause of concern for antibiotic resistance is in
nosocomial infections (Alanis, 2005) patients may well be ill, immu-
nosuppressed or debilitated before the onset of infection. This model
is ideally posed to explore these parameters.
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Fig. 3. Steady-state values for varying (a) Að0Þ ¼ A0, (b) A50R and ERmax (the last two simultaneously). Note that here and henceforth we plot only stable steady-states to
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Fig. 6 shows the effect of varying these host-speciﬁc para-
meters on the anti-virulence treatment. There exist circumstances
when anti-virulence drugs can be completely effective, however
these occur when either the baseline immune response or natural
ﬂow past the infection site is high. Thus it is possible that anti-
virulence drugs may only be successful in either treating or
preventing infection in an otherwise healthy individual. To test
infection prevention in a model, a more sophisticated set of
equations that captures a speciﬁc mechanism of action by an
anti-virulence drug, as opposed to our deliberately general con-
ceptual model, is required. This will be developed in future work.
In all cases examined here the population of antibiotic-resistant
bacteria is eliminated, due to their reduced ﬁtness making them
more vulnerable to the treatment. Thus, for an existing infection
requiring treatment, given that only susceptible bacteria remain,
we next examine the option of combining treatment by anti-
virulence drugs with conventional antibiotics.
3.5. Combination therapy: antibiotics and anti-virulence drugs
(Að0Þ ¼ 4 μg=ml, Anð0Þ ¼ 4 μg=ml)
Our results so far suggest that anti-virulence drugs would rid an
infection site of antibiotic-resistant but not antibiotic-susceptible
bacteria, so it would be expected that the addition of antibiotics to
this treatment would fully clear the infection. However, somewhat
surprisingly, Fig. 7a indicates that this is not necessarily the case (even
under the same default parameter set): though susceptible bacteria
are cleared, a number of resistant bacteria persist if the ﬁtness cost
associated with antibiotic resistance is sufﬁciently low. This may be
due to the dynamics of the immune cells: as the introduction of both
drugs rapidly decreases the population of susceptible bacteria we also
see a decline in the number of immune cells. Due to the dependence
of the anti-virulence drug on the immune system, this decline may
subsequently stunt the effectiveness of the drug, allowing the
antibiotic-resistant population to build up to a level with which the
immune system then cannot compete. In Fig. 7b, however, we see
that raising the ﬁtness cost to c¼0.27 can result in both subpopula-
tions being eliminated due to the additional weakness imposed on
the antibiotic-resistant bacteria (we note that this is just outside the
possible range for c suggested in Subbiah et al., 2011).
Excitingly, imposing a time delay on the administration of one
of the drugs can allow combination therapy to be successful
regardless of the ﬁtness cost, see Fig. 8. When c¼0.1, the infection
can be fully cleared if the antibiotic is administered after the anti-
virulence drugs, though the total bacterial load during this delay
greatly increases. Reversing the treatment order is also successful,
see Fig. 9. Here the delay is longer (and hence clearing the
infection takes longer) but the increase in bacterial load before
addition of the second drug is lower in this instance. Thus, we see
that in combining two treatments, one which is more effective
towards antibiotic-resistant bacteria and one which favours
antibiotic-susceptible bacteria, we can effectively eliminate all
bacteria provided a time delay is incorporated to enable both
drugs to have full effect.
So far, all our simulations have focused on an infection where
the antibiotic-resistant population are initially in the minority. In
Fig. 10 we consider the effect of this combination therapy on
an infection consisting entirely of antibiotic-resistant bacteria
(Sð0Þ ¼ 0;Rð0Þ ¼ 6000). Interestingly, though neither drug in isola-
tion will clear the infection (simulations not shown), the admin-
istration of both drugs with no time delay between them can clear
the infection provided c40:01 for our default parameter set. Thus
combining antibiotics and anti-virulence drugs can even be
successful in treating infections consisting solely of antibiotic-
resistant bacteria initially (remembering that we are considering
the bacteria to be partially resistant to the antibiotics and there is a
low rate of reversion from resistant to susceptible). In addition, if
we consider the scenario where antibiotic-resistance has occurred
via spontaneous chromosomal mutation (hence λ¼ ρ¼ 0) and no
ﬁtness cost is therefore incurred (c¼0), delayed combination
therapy again works, this time with delays of 0.03 days if the
anti-virulence drug is administered ﬁrst and 0.5 days if vice versa
(default initial conditions used, data not shown), again underlining
the need to fully understand the infection-type to design the
treatment strategy correctly.
4. Discussion
Bacterial resistance to antibiotics is an increasing problem in
today's society, more speciﬁcally in hospital settings where already
vulnerable patients are exposed to strains of bacteria upon which
conventional antibiotics have no effect. It has been widely suggested
that in order to combat this emergence of resistance, research focus
0 1 2 3 4 5 6 7 8
0
2000
4000
6000
8000
10000
12000
14000
16000
Time (days)
N
um
be
rs
 in
 P
op
ul
at
io
n
Susceptible bacteria, S
Resistant bacteria, R
Immune cells, P
0 1 2 3 4 5 6 7 8
0
2000
4000
6000
8000
10000
12000
14000
16000
Time (days)
N
um
be
rs
 in
 P
op
ul
at
io
n
Susceptible bacteria, S
Resistant bacteria, R
Immune cells, P
Fig. 5. Numerical solution to (1)–(5) when the infection is treated only by anti-virulence drugs (Að0Þ ¼ 0;Anð0Þ ¼ 4) (a) with doses every 0.5 days (κ ¼ 3:6) and (b) continuous
treatment (κ¼ 0). Though the antibiotic-resistant bacteria are quickly cleared from the infection, a subpopulation of antibiotic-susceptible bacteria persist because they grow
at a faster rate than the antibiotic-resistant bacteria. From the scale of the axes, S appears to have vanished on some intervals, but S41 holds for all time. The reduced
number of immune cells present at the infection site as a result of the treatment lowering the total bacterial load leaves the immune response incapable of clearing the
remaining susceptible bacteria. For the remainder of this study we consider only constantly administered anti-virulence drug for simplicity (κ ¼ 0).
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needs to shift from developing new antibiotics to novel treatment
strategies that target bacterial virulence: an anti-virulence drug that
promotes natural clearance through a weakening of their ability to
counteract the immune response. This has given rise to much
discussion of the potential success of such an approach with
experimental investigations revealing, in general, attenuation but
not clearance of infections. Would these drugs be better suited to
infection prevention or can they be enhanced to treat existing
infections? Since these drugs are still in the very early stages of
development, we have developed a mathematical model to test their
potential efﬁcacy and treatment strategies in silico.
Our model suggests that, if used in isolation, an anti-virulence
drug may not be capable of clearing an infection as it relies too
heavily on the host immune system which was not strong enough to
clear the infection itself in the ﬁrst place (hence the need for
treatment). The immune-related parameters are highly host-speciﬁc,
though, and if taken to be representative of a healthy individual then
the anti-virulence drug could well deal with an infection, suggesting
that the drug could be useful for prophylaxis. However, since
antibiotic resistance is mainly a problem in hospital settings, where
patients are more vulnerable and are likely to have a weaker immune
response, this dependence on the immune system is likely to be a
limitation of the proposed treatment. Nevertheless, regardless of not
being able to completely clear the bacterial infection in such
immunocompromised patients, we do ﬁnd some promising results.
The persisting bacterial load is not only at a much lower level than the
model predicted after antibiotic treatment (remembering that the
simulated infection consists of a mixed population of antibiotic-
susceptible and -resistant bacteria), but importantly the antibiotic-
resistant bacteria were eliminated (due to the ﬁtness cost associated
with resistance) leaving only antibiotic-susceptible bacteria at the
infection site. These results led us to investigate the potential of
combination therapy. Treatment by both anti-virulence drugs and
antibiotics could fully clear an infection if the ﬁtness cost associated
with antibiotic-resistance was sufﬁciently high. If this cost was lower,
combination therapy could still be successful through the imposition
of a time delay between treatment types, but the success of this
approach was sensitive to the choice of delay between the drug types.
This ‘delay’ result is not intuitive and highlights the beneﬁts of
adopting a modelling approach.
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Fig. 6. Steady-state values of bacteria and phagocyte levels under anti-virulence treatment when (a) natural clearance (ψ) and (b) baseline immune response (γ) are varied.
The bacteria can be cleared from the infection but only when these host-speciﬁc parameters are sufﬁciently strong. We note that the critical values of ψ and γ above which all
bacteria will be cleared are lower in the discontinuous model stated in (1)–(5) (around ψ  12 and γ  0:01) than in these ﬁgures due to the rule that S or R can only degrade
when So1 or Ro1 in the time-dependent solutions (recall that this rule is removed to generate steady-state diagrams from continuous equations in XPPAUT).
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Fig. 7. Simulation of combination therapy (Að0Þ ¼ Anð0Þ ¼ 4; α¼ κ¼ 0) with (a) c¼0.1 and (b) c¼0.27. The combined treatments are only successful if the ﬁtness cost
associated with antibiotic resistance is sufﬁciently high.
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Fig. 8. Predicted results of administering an anti-virulence drug to the infection site, with the addition of an antibiotic after (a) 0.01 days and (b) 0.02 days when c¼0.1. If the
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Fig. 9. Predicted results of administering an antibiotic to the infection site, followed by an anti-virulence drug after (a) 0.5 days and (b) 0.6 days with c¼0.1. The required
delay between drugs for clearance of the infection is longer if the drugs are administered in this order than vice versa (compare with Fig. 8).
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Fig. 10. An infection consisting solely of (partially) antibiotic-resistant bacteria (Sð0Þ ¼ 0;Rð0Þ ¼ 6000) treated by both antibiotics and anti-virulence drugs simultaneously
with (a) c¼0.01 and (b) c¼0.02. The combination therapy is capable of clearing the infection, but only if the ﬁtness cost of antibiotic resistance is sufﬁciently high.
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While underpinning the potential of anti-virulence drugs in a
theoretical framework, this study also highlights the beneﬁts of
better understanding patient- and site-speciﬁc parameters perti-
nent to an infection in order to use a mathematical model to
predict required treatment strategies. Though some (but not all) of
the parameter surveys presented in this study are fairly intuitive,
they illustrate the usefulness of mathematical models in this
context. Treatment strategies are likely to be dependent on speciﬁc
parameters within an infection, for example the level of resistance
the infecting strain displays to a particular antibiotic, the likely
bacterial load at an infection site or the time taken for treatment to
reach the infection site. Thus, mathematical modelling will prove
an extremely useful tool to provide tailored treatments that will
optimise our use of drugs (unlike what has been seen with the
over- and often mis-use of antibiotics).
The model can be extended to represent a speciﬁc anti-virulence
drug. For example, anti-adhesive drugs that prevent bacteria binding to
host cells should increase the natural clearance rate and this can be
accounted for in extensions to the model. Such efforts will greatly
enhance the predictive powers of this type of model and contribute to
the future design of effective treatment regimen for bacterial infections.
Crucially, these extensions to the model will also facilitate predictions
on the likelihood that bacteria develop resistance to anti-virulence
drugs in general and on whether the speciﬁc target of the drug will
impact upon this, as argued in Allen et al. (2014). Our preliminary
modelling investigations suggest that anti-virulence drug-resistance
could emerge during an infection. However, for anti-virulence drug-
resistance to emerge, the bacteria need to be more resilient to the drug
than they do against antibiotics for antibiotic-resistance to emerge. We
stress, though, that these are very early ﬁndings: the breadth of anti-
virulence targets and resistance mechanisms makes this a task beyond
the scope of the current study.
5. Conclusions
Antibiotic resistance in bacteria has long been recognised as a
problem for effective treatment of infections, yet it is only more
recently that the urgent need for antibiotic alternatives has become
widely accepted. We have presented here a model of a generalised
treatment strategy for changing the target of the drug to promote
natural clearance. Our results support the continuation of research
into anti-virulence drugs both in the context of treating infections
and in aiding with the elimination of the spread of antibiotic-
resistant bacteria from an infection and through hospital settings.
Throughout our analysis of these models we have highlighted
some important issues that need to be considered when designing
treatment strategies such as the importance of tailoring treatment to
speciﬁc conditions of the host and how the success of combination
therapy (use of more than one drug type) depends critically on the
dosing schedule. Most importantly, however, we have shown condi-
tions under which treatment strategies will be successful (some of
which are non-intuitive) and hence provided a proof of concept for
the potential such treatments should have to help eliminate the
problem of antibiotic resistance.
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